التفاصيل البيبلوغرافية
| العنوان: |
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly. |
| المؤلفون: |
Chiloiro, Sabrina, Giampietro, Antonella, Giambò, Penelope, Costanza, Flavia, Mattogno, Pier Paolo, Lauretti, Liverana, Calandrelli, Rosalinda, Gaudino, Simona, Gessi, Marco, Rindi, Guido, Olivi, Alessandro, De Marinis, Laura, Doglietto, Francesco, Bianchi, Antonio, Pontecorvi, Alfredo, Giustina, Andrea |
| المصدر: |
Pituitary; Feb2025, Vol. 28 Issue 1, p1-12, 12p |
| مستخلص: |
Introduction: First-generation somatostatin receptor ligands (fg-SRLs) are the cornerstone of acromegaly treatment. Additional benefits were shown using high dose (HD) or high frequency (HF), relatively short-term regimens. Although several predictors of response to standard dose (SD)-fg-SRLs were reported, outcome biomarkers for HF administration are not yet available. Here, we aimed to identify predictors of response to long-term HF-fg-SRLs. Patients and methods: A retrospective study was performed on 102 patients, treated with Lanreotide. Patients not controlled at 12 months of SD-Lanreotide (120 mg/28 days) were switched to HF-Lanreotide (120 mg/21 days) for additional 12 months. Results: Twenty-eight patients were controlled at 6 months of SD-Lanreotide (27.4%); 35 patients were controlled at 12 months of treatment (34.3%). Out of 67 patients treated with HF- Lanreotide, 18 (26.9%) were controlled at 6 months of treatment and remained controlled until 12 months. Both during SD and HF-Lanreotide administrations, IGF-I levels were reduced during the first six months of treatment (p < 0.001), without further significant reduction between 6 and 12 months of therapy. Response at 12 months of SD-Lanreotide was predicted by IGF-I reached at six months of SD-Lanreotide (p = 0.024). Response at 12 months of HF-Lanreotide treatment was predicted by IGF-I levels reached at six months of SD-Lanreotide treatment (p = 0.04) and six months of HF-Lanreotide treatment (p = 0.01). Conclusion: Our results demonstrated that initial IGF-I levels during SD-Lanreotide predicted the biochemical outcome after 12 months of HF-Lanreotide. Patients in whom HF-Lanreotide did not normalize IGF-I after 6 months of treatment remained uncontrolled 12 months after starting this regimen. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pituitary is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |